vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and INSTEEL INDUSTRIES INC (IIIN). Click either name above to swap in a different company.

Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $159.9M, roughly 1.1× INSTEEL INDUSTRIES INC). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 23.3%). Over the past eight quarters, INSTEEL INDUSTRIES INC's revenue compounded faster (12.0% CAGR vs 10.6%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Insteel Industries Inc is a leading U.S. manufacturer of steel reinforcing products including welded wire reinforcement and steel fibers. It primarily serves non-residential construction, infrastructure, and precast concrete segments across North America, delivering high-performance reinforcement solutions for various construction projects.

ESPR vs IIIN — Head-to-Head

Bigger by revenue
ESPR
ESPR
1.1× larger
ESPR
$168.4M
$159.9M
IIIN
Growing faster (revenue YoY)
ESPR
ESPR
+120.4% gap
ESPR
143.7%
23.3%
IIIN
Faster 2-yr revenue CAGR
IIIN
IIIN
Annualised
IIIN
12.0%
10.6%
ESPR

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ESPR
ESPR
IIIN
IIIN
Revenue
$168.4M
$159.9M
Net Profit
$7.6M
Gross Margin
11.3%
Operating Margin
50.6%
6.0%
Net Margin
4.7%
Revenue YoY
143.7%
23.3%
Net Profit YoY
602.4%
EPS (diluted)
$0.32
$0.39

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
IIIN
IIIN
Q4 25
$168.4M
$159.9M
Q3 25
$87.3M
$177.4M
Q2 25
$82.4M
$179.9M
Q1 25
$65.0M
$160.7M
Q4 24
$69.1M
$129.7M
Q3 24
$51.6M
$134.3M
Q2 24
$73.8M
$145.8M
Q1 24
$137.7M
$127.4M
Net Profit
ESPR
ESPR
IIIN
IIIN
Q4 25
$7.6M
Q3 25
$-31.3M
$14.6M
Q2 25
$-12.7M
$15.2M
Q1 25
$-40.5M
$10.2M
Q4 24
$1.1M
Q3 24
$-29.5M
$4.7M
Q2 24
$-61.9M
$6.6M
Q1 24
$61.0M
$6.9M
Gross Margin
ESPR
ESPR
IIIN
IIIN
Q4 25
11.3%
Q3 25
16.1%
Q2 25
17.1%
Q1 25
15.3%
Q4 24
7.3%
Q3 24
9.1%
Q2 24
10.6%
Q1 24
12.3%
Operating Margin
ESPR
ESPR
IIIN
IIIN
Q4 25
50.6%
6.0%
Q3 25
-11.4%
10.8%
Q2 25
8.6%
11.0%
Q1 25
-34.0%
8.3%
Q4 24
-6.4%
1.1%
Q3 24
-31.0%
4.5%
Q2 24
3.5%
6.0%
Q1 24
52.5%
7.0%
Net Margin
ESPR
ESPR
IIIN
IIIN
Q4 25
4.7%
Q3 25
-35.9%
8.2%
Q2 25
-15.4%
8.4%
Q1 25
-62.2%
6.4%
Q4 24
0.8%
Q3 24
-57.2%
3.5%
Q2 24
-83.9%
4.5%
Q1 24
44.3%
5.4%
EPS (diluted)
ESPR
ESPR
IIIN
IIIN
Q4 25
$0.32
$0.39
Q3 25
$-0.16
$0.74
Q2 25
$-0.06
$0.78
Q1 25
$-0.21
$0.52
Q4 24
$-0.14
$0.06
Q3 24
$-0.15
$0.24
Q2 24
$-0.33
$0.34
Q1 24
$0.34
$0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
IIIN
IIIN
Cash + ST InvestmentsLiquidity on hand
$167.9M
$15.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$-302.0M
$358.8M
Total Assets
$465.9M
$456.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
IIIN
IIIN
Q4 25
$167.9M
$15.6M
Q3 25
$92.4M
$38.6M
Q2 25
$86.1M
$53.7M
Q1 25
$114.6M
$28.4M
Q4 24
$144.8M
$36.0M
Q3 24
$144.7M
$111.5M
Q2 24
$189.3M
$97.7M
Q1 24
$226.6M
$83.9M
Stockholders' Equity
ESPR
ESPR
IIIN
IIIN
Q4 25
$-302.0M
$358.8M
Q3 25
$-451.4M
$371.5M
Q2 25
$-433.5M
$356.2M
Q1 25
$-426.2M
$341.4M
Q4 24
$-388.7M
$331.6M
Q3 24
$-370.2M
$350.9M
Q2 24
$-344.2M
$346.0M
Q1 24
$-294.3M
$340.6M
Total Assets
ESPR
ESPR
IIIN
IIIN
Q4 25
$465.9M
$456.1M
Q3 25
$364.0M
$462.6M
Q2 25
$347.1M
$471.9M
Q1 25
$324.0M
$421.9M
Q4 24
$343.8M
$404.7M
Q3 24
$314.1M
$422.6M
Q2 24
$352.3M
$414.6M
Q1 24
$373.1M
$397.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
IIIN
IIIN
Operating Cash FlowLast quarter
$45.2M
$-701.0K
Free Cash FlowOCF − Capex
$-2.2M
FCF MarginFCF / Revenue
-1.4%
Capex IntensityCapex / Revenue
0.0%
0.9%
Cash ConversionOCF / Net Profit
-0.09×
TTM Free Cash FlowTrailing 4 quarters
$439.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
IIIN
IIIN
Q4 25
$45.2M
$-701.0K
Q3 25
$-4.3M
$-17.0M
Q2 25
$-31.4M
$28.5M
Q1 25
$-22.6M
$-3.3M
Q4 24
$-35.0M
$19.0M
Q3 24
$-35.3M
$16.2M
Q2 24
$-7.2M
$18.8M
Q1 24
$53.8M
$1.4M
Free Cash Flow
ESPR
ESPR
IIIN
IIIN
Q4 25
$-2.2M
Q3 25
$-18.7M
Q2 25
$26.9M
Q1 25
$-5.5M
Q4 24
$16.3M
Q3 24
$-35.5M
$14.5M
Q2 24
$-7.3M
$15.5M
Q1 24
$53.8M
$-580.0K
FCF Margin
ESPR
ESPR
IIIN
IIIN
Q4 25
-1.4%
Q3 25
-10.6%
Q2 25
15.0%
Q1 25
-3.5%
Q4 24
12.6%
Q3 24
-68.7%
10.8%
Q2 24
-9.9%
10.7%
Q1 24
39.0%
-0.5%
Capex Intensity
ESPR
ESPR
IIIN
IIIN
Q4 25
0.0%
0.9%
Q3 25
0.0%
1.0%
Q2 25
0.0%
0.9%
Q1 25
0.0%
1.4%
Q4 24
0.0%
2.1%
Q3 24
0.3%
1.3%
Q2 24
0.1%
2.2%
Q1 24
0.1%
1.5%
Cash Conversion
ESPR
ESPR
IIIN
IIIN
Q4 25
-0.09×
Q3 25
-1.17×
Q2 25
1.88×
Q1 25
-0.32×
Q4 24
17.56×
Q3 24
3.48×
Q2 24
2.86×
Q1 24
0.88×
0.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

IIIN
IIIN

Welded Wire Reinforcement$108.4M68%
PC Strand$51.6M32%

Related Comparisons